NCT06120036View on ClinicalTrials.gov

Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 6, 2022

Primary Completion Date

January 9, 2025

Study Completion Date

January 9, 2025

Conditions
Neurofibromatosis 1
Interventions
DRUG

Kybella

Injection into the cutaneous Neurofibromas lesion.

DRUG

Asclera

Injection into the cutaneous Neurofibromas lesion.

Trial Locations (1)

02114

Wellman Center for Photomedicine, Boston

All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

lead

Massachusetts General Hospital

OTHER